Equity Profile

MEDP

Medpace Holdings, Inc.

Health CareLife Sciences Tools & Services$15.1B

Jul20Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Medpace Holdings, Inc. is a leading global contract research organization that provides comprehensive services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, crucial for investor sentiment.

$4.00

Revenue

Total revenue reflects the company's ability to generate sales and is vital for assessing growth potential.

$690M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Medpace Holdings, Inc. is a leading global contract research organization that provides comprehensive services to the pharmaceutical and biotechnology industries. Operating in the health care sector, Medpace plays a crucial role in helping companies develop new drugs and therapies, making it significant in the ongoing advancements in life sciences.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

In Q1-2026, Medpace reported an EPS of $4.28, significantly surpassing analyst expectations. However, the stock declined by 1.25% the following day, indicating market skepticism despite the strong earnings.

Management Promises & Guidance

Continued focus on expanding service offerings in clinical development.
Commitment to maintaining high client satisfaction and retention rates.
Plans to enhance operational efficiencies to support growth.

Expectations

Wall Street Expectations

Analysts expect Medpace to report strong earnings again, with a consensus EPS of $4.00. The market is keenly watching for any signs of sustained growth in revenue and profitability.

Bull Case

If Medpace exceeds EPS expectations and shows robust revenue growth, it could signal strong demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about future growth, leading to a potential sell-off.

Key Metrics to Watch

EPS

$4.00

Earnings per share is a key indicator of the company's profitability and financial health, crucial for investor sentiment.

Revenue

$690M

Total revenue reflects the company's ability to generate sales and is vital for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $4.00?

A beat on EPS would reinforce the company's growth narrative and could lead to a positive market reaction.

What guidance will management provide regarding revenue growth for the upcoming quarters?

Clear guidance on revenue growth will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Medpace's ability to capitalize on increasing demand for clinical trial services, driven by a growing pharmaceutical pipeline.

Supporting Evidence

Recent trends in the pharmaceutical industry indicate a surge in drug development activities, which could benefit Medpace.

The options market is pricing in a significant move, suggesting that investors are anticipating a larger reaction than historical averages.

Insider buying activity could indicate confidence in the company's future performance.

Key Risk

If revenue growth significantly outpaces expectations, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce Medpace's growth story or highlight potential weaknesses in demand.

Bull Confirmed If

An EPS of $4.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $3.80 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations, history suggests the stock could rise by an average of 1.49%, confirming the strength of its business model.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to muted stock movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of 1.49% in such scenarios.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships.
2Details on operational efficiencies and cost management strategies.
3Insights into market demand for clinical trial services.
4Management's outlook on the competitive landscape.
5Any commentary on potential regulatory impacts on operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Medpace Holdings, Inc. is a leading global contract research organization that provides comprehensive services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, crucial for investor sentiment.

$4.00

Revenue

Total revenue reflects the company's ability to generate sales and is vital for assessing growth potential.

$690M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding service offerings in clinical development.
Commitment to maintaining high client satisfaction and retention rates.
Plans to enhance operational efficiencies to support growth.

Expectations

Wall Street Expectations

Analysts expect Medpace to report strong earnings again, with a consensus EPS of $4.00. The market is keenly watching for any signs of sustained growth in revenue and profitability.

Bull Case

If Medpace exceeds EPS expectations and shows robust revenue growth, it could signal strong demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about future growth, leading to a potential sell-off.

Key Metrics to Watch

EPS

$4.00

Earnings per share is a key indicator of the company's profitability and financial health, crucial for investor sentiment.

Revenue

$690M

Total revenue reflects the company's ability to generate sales and is vital for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $4.00?

A beat on EPS would reinforce the company's growth narrative and could lead to a positive market reaction.

What guidance will management provide regarding revenue growth for the upcoming quarters?

Clear guidance on revenue growth will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Medpace's ability to capitalize on increasing demand for clinical trial services, driven by a growing pharmaceutical pipeline.

Supporting Evidence

Recent trends in the pharmaceutical industry indicate a surge in drug development activities, which could benefit Medpace.

The options market is pricing in a significant move, suggesting that investors are anticipating a larger reaction than historical averages.

Insider buying activity could indicate confidence in the company's future performance.

Key Risk

If revenue growth significantly outpaces expectations, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce Medpace's growth story or highlight potential weaknesses in demand.

Bull Confirmed If

An EPS of $4.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $3.80 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations, history suggests the stock could rise by an average of 1.49%, confirming the strength of its business model.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to muted stock movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of 1.49% in such scenarios.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships.
2Details on operational efficiencies and cost management strategies.
3Insights into market demand for clinical trial services.
4Management's outlook on the competitive landscape.
5Any commentary on potential regulatory impacts on operations.